First Trust North American Energy Infrastructure Fund (ARCA: EMLP)

First Trust North American Energy Infrastructure Fund (ARCA:EMLP), Trade Ideas

First Trust North American Energy Infrastructure Fund

Analyst Color

Long Ideas

Sector ETFs

Broad U.S. Equity ETFs

Analyst Ratings

Trading Ideas

ETFs

ARKK

EMLP

TSLA

Active Equity ETFs Are Coming Of Age

News

Short Ideas

Dividends

Commodities

Intraday Update

Markets

Kinder Morgan Is A Drag On This ETF

Bonds

Specialty ETFs

New ETFs

BOND

Pimco Enhanced Short Maturity Strategy Fund

MINT

TOTL

Gundlach&#39;s First ETF Is A Smash Hit, Tops $1 Billion In Assets

Enabled by high-capacity batteries, this key technology seeks to enhance security for users, ensure the conformity of all system components, and deliver an elevated boating experience.

VMAR

Vision Marine Technologies Says It Filed Patent For Advanced System Communication Encryption In E-Motion Powertrain

Needham analyst Laura Martin reiterates Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Buy and maintains $100 price target.

Price Target

Reiteration

ROKU

Needham Reiterates Buy on Roku, Maintains $100 Price Target

Earnings

Large Cap

Guidance

Health Care

General

ABBV

AbbVie Is Raising Its 2024 Adjusted EPS Guidance From $10.97-$11.17 To $11.13-$11.33, Which Includes An Unfavorable Impact Of $0.08 Per Share Related To Acquired IPR&D And Milestones Expense, Versus Consensus Of $11.12

For the first quarter, the Company expects revenue to increase over 40% year-over-year and come in between $18.5 million and $19.2 million with a GAAP net loss and Adjusted EBITDA loss between $(8.2) - $(7.0) million and $(1.0) - $(0.7) million, respectively (see definition of this non-GAAP measure and reconciliation to GAAP, below). The year-over-year revenue increase was primarily driven by strong organic growth due to our Dynamic Audience Activation Platform (DAAP) as well as from our October 2023 acquisition of Medicx Health.
Steve Silvestro, OptimizeRx President commented, "The momentum from the fourth quarter has carried into the first quarter of 2024 with the signing of 9 new DAAP deals. Current industry trends favor our approach with pharma looking to partner with scalable platforms that have agile precision-marketing capabilities which at its core is what our AI enabled platform delivers."
"Our commercial integration strategy between OptimizeRx and Medicx is also progressing ahead of our expectations, with numerous new cross-sell opportunities in late-stage negotiations. The integration of the two businesses is ahead of schedule and we are optimistic about our performance. With the addition of Medicx, we stand out as the only scalable platform with both HCP and direct-to-consumer reach. This unique positioning enhances our ability to cross-sell and upsell, unlocking significant value. We estimate the potential opportunity with existing brands alone to be nearly $2.8 billion, with even greater potential for brands we don't yet support. This favorable environment strengthens our confidence in meeting or exceeding our financial targets."

OPRX

OptimizeRx Corporation Says 1Q24 Revenue Expected To Grow Over 40% YoY And Come In Between $18.5M-$19.2M Vs. $17.03M Estimate; Company Says DAAP Adoption And Cross Selling Activities Are Tracking Ahead Of Internal Expectations

HC Wainwright &amp; Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and maintains $41 price target.

SNDX

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target

Mizuho analyst Vijay Rakesh maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Buy and lowers the price target from $55 to $45.

INTC

Mizuho Maintains Buy on Intel, Lowers Price Target to $45

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported quarterly earnings of $2.31 per share which beat the analyst consensus estimate of $2.23 by 3.59 percent. This is a 6.1 percent decrease over earnings of $2.46 per share from the same period last year. The company reported quarterly sales of $12.310 billion which beat the analyst consensus estimate of $11.923 billion by 3.25 percent. This is a 0.70 percent increase over sales of $12.225 billion the same period last year.

Earnings Beats

AbbVie Q1 2024 Adj EPS $2.31 Beats $2.23 Estimate, Sales $12.310B Beat $11.923B Estimate

Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Biohaven</h3>
<ul>
<li>The Trade: Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) Director Gregory Bailey <a href="https://www.benzinga.com/quote/BHVN/analyst-ratings">acquired a total of 25,503 shares</a> at an average price of $39.18. To acquire these shares, it cost around $999,169.</li>
<li>What's Happening: On April 18, Biohaven priced a 5.609 million share offering at $41 per share.</li>
<li>What Biohaven Does: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.</li>
</ul>
<h3 class="wp-block-heading">authID</h3>
<ul>
<li>The Trade: authID Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) 10% owner Stephen Jeffrey Garchik acquired a total of 12,000 shares at an average price of $6.85. To acquire these shares, it cost around $82,200.</li>
<li>What's Happening: On March 20, authID posted a narrower FY23 loss.</li>
<li>What authID Does: AuthID Inc is a company engaged in ensuring cyber-savvy enterprises &#8220;Know Who&#8217;s Behind the Device&#8221; for every customer or employee login and transaction.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h3 class="wp-block-heading">Frequency Electronics</h3>
<ul>
<li>The Trade: Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) Director Russell M Sarachek <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 1,602 shares</a> at an average price of $9.51. To acquire these shares, it cost around $15,235.</li>
<li>What's Happening: On March 14, Frequency Electronics posted a narrower third-quarter loss.</li>
<li>What Frequency Electronics Does: Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications.</li>
</ul>
<h3 class="wp-block-heading">Bank7</h3>
<ul>
<li>The Trade: Bank7 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSVN#NASDAQ">BSVN</a>) Director Edward Patrick Gray <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 1,000 shares</a> at an average price of $27.25. The insider spent around $27,254 to buy those shares.</li>
<li>What's Happening: On April 12, Bank7 posted upbeat quarterly earnings.</li>
<li>What Bank7 Does: Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a wide variety of commercial and retail financial services.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38452338/microsoft-alphabet-and-3-stocks-to-watch-heading-into-friday">Microsoft, Alphabet And 3 Stocks To Watch Heading Into Friday</a>

Insider Trades

Pre-Market Outlook

AUID

BHVN

BSVN

FEIM

Around $1M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying

WIIM

AMZN

Amazon.com shares are trading higher following strong earnings from large-cap tech companies.

HCA Healthcare Reaffirms 2024 EPS Guidance Of $19.70-$21.20 Versus Consensus Of $20.68

Mizuho analyst James Lee maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Buy and raises the price target from $170 to $190.

GOOG

GOOGL

Mizuho Maintains Buy on Alphabet, Raises Price Target to $190

MSFT

Microsoft shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 and FY25 guidance. Also, multiple firms raised their respective price targets on the stock.

HCA Healthcare Reaffirms 2024 Revenue Guidance Of $67.75B-$70.25B Versus Consensus Of $69.12B

Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) reported quarterly earnings of $3.38 per share which missed the analyst consensus estimate of $3.44 by 1.74 percent. The company reported quarterly sales of $754.775 million which missed the analyst consensus estimate of $770.665 million by 2.06 percent. This is a 14.27 percent increase over sales of $660.535 million the same period last year.

Earnings Misses

SAIA

Saia Q1 2024 GAAP EPS $3.38 Misses $3.44 Estimate, Sales $754.775M Miss $770.665M Estimate

On Thursday, April 25th, the U.S. stock markets closed lower, impacted by surprising data indicating sluggish U.S. economic expansion and ongoing inflation. This downturn&nbsp;was exacerbated&nbsp;by a broad sell-off in major stocks following&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38430266/meta-platforms-stock-is-tumbling-thursday-whats-going-on" rel="noreferrer noopener">underwhelming earnings from Meta Platforms</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38441148/metas-q1-earnings-analysts-say-support-its-ai-strategy-use-meta-as-a-source-of-fund" rel="noreferrer noopener">Meta&#8217;s Q1 Earnings: Most Analysts Support AI Strategy, While One Says &#8216;Use Meta As A Source Of Funds,&#8217; Questions Its Long-Term Value</a>
The U.S. economy grew at an annualized rate of 1.6% in the first quarter, slowing from 3.4% in the previous quarter and falling short of the expected 2.5% growth.&nbsp;
The core personal consumption expenditures price index rose 3.7% annually, up from 2% in the previous quarter.
Communications stocks, notably affected by Meta, led&nbsp;losses in&nbsp;the S&amp;P 500, with healthcare, real estate, financials, consumer staples, and consumer discretionary sectors also falling.
The Dow Jones Industrial Average declined 0.98% to close at 38,085.80. The S&amp;P 500 was down 0.46%, ending the day at 5,048.42, and the Nasdaq Composite slid 0.64%, finishing the session at 15,611.76.
Asia Markets Today
<ul>
<li>On Friday, Japan&#8217;s Nikkei 225 index closed higher by 0.84% at 37,943.50, led by gains in the Precision Instruments, Transportation Equipment, and Electrical/Machinery sectors.</li>
<li>In Australia, the&nbsp;S&amp;P/ASX 200 index closed the session lower by 1.39% at 7,575.90, led by losses in the Industrials, A-REITs, and Telecoms Services sectors.</li>
<li>India&#8217;s Nifty 50 declined 0.67% to close at 22,419.95, and the Nifty 500 slipped 0.14%, closing at 20,839.35.</li>
<li>China&#8217;s Shanghai Composite gained 1.17% to end the session at 3,088.64, and the Shenzhen CSI 300 rose 1.53%, closing at 3,584.27.</li>
<li>Hong Kong&#8217;s Hang Seng Index gained 2.12%, concluding the day at 17,651.15.</li>
</ul>
Eurozone at 06:15 AM ET
<ul>
<li>The European STOXX 50 index was up 0.69%.</li>
<li>Germany&#8217;s DAX gained 0.72%.</li>
<li>France&#8217;s CAC climbed 0.27%.</li>
<li>U.K.&#8217;s FTSE 100 traded higher&nbsp;by&nbsp;0.41%.</li>
</ul>
Commodities at 06:15 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.44% at $83.92/bbl, and Brent was up 0.43% at $89.39 bbl.</li>
<li>Natural Gas declined 1.21% to $1.962.</li>
<li>Gold was trading higher by 0.73% at $2,359.60, Silver gained 1.18% to $27.675, while Copper was up 1.41% at $4.5815.</li>
</ul>
US Futures at 06:15 AM ET&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dow futures were up 0.12%, S&amp;P 500 futures rose 0.65%, and Nasdaq 100 Futures gained 0.92%.
Forex at 06:15 AM ET
The U.S. Dollar Index gained 0.05% to 105.65, USD/JPY was up 0.73% to 156.79, and USD/AUD slipped 0.23% to 1.5305.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Crude And Gold Trade Higher; Major Asia Indexes And Europe Rise - Global Markets Today While US Slept

IONQ

IonQ Appoints Peter Chapman As Next Chairman Of Board Of Directors; Company Hires Harry You As Lead Independent Director Of The Board

HCA Healthcare's Q1 Same Facility Admissions Increased 6.2% While Same Facility Equivalent Admissions Increased 5.2%

Morgan Stanley analyst Adam Jonas downgrades Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) from Equal-Weight to Underweight and lowers the price target from $26 to $25.

Downgrades

MBLY

Morgan Stanley Downgrades Mobileye Global to Underweight, Lowers Price Target to $25

TEAM

Atlassian shares are trading lower afer the company reported Q3 financial results. Also, the comapny announced that Co-CEO Scott Farquhar will step down.

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) reported quarterly earnings of $5.36 per share which beat the analyst consensus estimate of $5.01 by 6.99 percent. This is a 8.72 percent increase over earnings of $4.93 per share from the same period last year. The company reported quarterly sales of $17.339 billion which beat the analyst consensus estimate of $16.779 billion by 3.33 percent. This is a 11.21 percent increase over sales of $15.591 billion the same period last year.

HCA Healthcare Q1 2024 Adj EPS $5.36 Beats $5.01 Estimate, Sales $17.339B Beat $16.779B Estimate

First Trust Energy Infrastructure: A Closed-End Fund's ETF Conversion

First Trust North American Energy Infrastructure Fund declares quarterly distribution of $0.2415

Led By MLPs, Midstream Is Energy Bright Spot In 2023

EIA Short-Term Energy Outlook And Tight Oil Update, December 2023

2024 Outlook: Macro Uncertainty Favors Midstream/MLPs

Why You Should Consider MLPs For Your Income Portfolio

Accessing MLPs/Midstream Through ETNs

MLPA: High-Yield ETF Topping 7%

The Staying Power Of Oil And Gas Pipelines

First Trust North American Energy Infrastructure Fund declares $0.2636 dividend

AMLP

AMNA

AMND

AMTR

AMUB

AMZA

ATMP

EINC

ENFR

ENLC

ETRN

JJETF

MLPA

MLPB

MLPO

MLPX

OILK

OLOXF

PAGP

TPYP

TRGP

USAI

USOI